| Item Type | Name |
|
Academic Article
|
Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.
|
|
Academic Article
|
Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.
|
|
Academic Article
|
Docetaxel followed by gemcitabine and irinotecan in solid tumors.
|
|
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
|
Concept
|
Chemotherapy, Adjuvant
|
|
Concept
|
Drug Therapy, Combination
|
|
Concept
|
Drug Therapy
|
|
Academic Article
|
Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.
|
|
Academic Article
|
Update on pancreatic cancer.
|
|
Academic Article
|
Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas.
|
|
Academic Article
|
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.
|
|
Academic Article
|
Proximal Splenic Artery Embolization in Chemotherapy-Induced Thrombocytopenia: A Retrospective Analysis of 13 Patients.
|
|
Academic Article
|
Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma.
|
|
Academic Article
|
Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer.
|
|
Academic Article
|
Novel advances in pancreatic cancer treatment.
|
|
Academic Article
|
Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study.
|
|
Academic Article
|
Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.
|
|
Academic Article
|
Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial.
|
|
Academic Article
|
Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer.
|
|
Academic Article
|
A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
|
|
Academic Article
|
Irinotecan in the management of patients with pancreatic cancer.
|
|
Academic Article
|
Oxaliplatin and fixed-rate infusional gemcitabine in the second-line treatment of patients with metastatic colon cancer: final results of a Phase II trial prematurely closed as a result of poor accrual.
|
|
Academic Article
|
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.
|
|
Academic Article
|
Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.
|
|
Academic Article
|
Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.
|
|
Academic Article
|
Timing of adjuvant and neoadjuvant therapy in colorectal cancers.
|
|
Academic Article
|
Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.
|
|
Academic Article
|
Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma?
|
|
Academic Article
|
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.
|
|
Academic Article
|
Is adjuvant 5-FU-based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question.
|
|
Academic Article
|
A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
|
|
Academic Article
|
Methylation-mediated silencing of TMS1 in pancreatic cancer and its potential contribution to chemosensitivity.
|
|
Academic Article
|
A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors.
|
|
Academic Article
|
Irinotecan and gemcitabine in patients with solid tumors: phase I trial.
|
|
Academic Article
|
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
|
|
Academic Article
|
Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC).
|
|
Academic Article
|
Radiation and chemotherapy for patients with stage III non-small cell lung cancer.
|
|
Academic Article
|
Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report.
|
|
Academic Article
|
Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.
|
|
Academic Article
|
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
|
|
Academic Article
|
Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment.
|
|
Academic Article
|
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
|
|
Academic Article
|
Topoisomerase I-based nonplatinum combinations in non-small-cell lung cancer.
|
|
Academic Article
|
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.
|
|
Academic Article
|
New directions in the management of advanced pancreatic cancer: a review.
|
|
Academic Article
|
A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan.
|
|
Academic Article
|
Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
|
|
Academic Article
|
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
|
|
Academic Article
|
Metastatic colorectal cancer: systemic treatment in the new millennium.
|
|
Academic Article
|
Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer.
|
|
Academic Article
|
Emphysematous cholecystitis in a patient with gastrointestinal stromal tumor treated with sunitinib.
|
|
Academic Article
|
Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.
|
|
Academic Article
|
Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.
|
|
Academic Article
|
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
|
|
Academic Article
|
Docetaxel in the management of advanced pancreatic cancer.
|